A secondary carboxamide resulting from the formal condensation of the carboxy group of 6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]pyridine-3-carboxylic acid with the amino group of neopentylamine. It is a potent p38alpha/beta mitogen activated protein kinase inhibitor which was previously in clinical trials for the treatment of facioscapulohumeral muscular dystrophy -- trial now discontinued due to not achieving its primary endpoint. ChEBI: 6-[5-[(cyclopropylamino)-oxomethyl]-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)-3-pyridinecarboxamide is a phenylpyridine.